WO2001030324A3 - Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia - Google Patents

Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia Download PDF

Info

Publication number
WO2001030324A3
WO2001030324A3 PCT/AT2000/000282 AT0000282W WO0130324A3 WO 2001030324 A3 WO2001030324 A3 WO 2001030324A3 AT 0000282 W AT0000282 W AT 0000282W WO 0130324 A3 WO0130324 A3 WO 0130324A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostatic hyperplasia
treatment
acetylsalicylic acid
preparation
prostatic
Prior art date
Application number
PCT/AT2000/000282
Other languages
German (de)
French (fr)
Other versions
WO2001030324A2 (en
Inventor
Joachim G Aufsess
Original Assignee
Joachim G Aufsess
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joachim G Aufsess filed Critical Joachim G Aufsess
Priority to AU10067/01A priority Critical patent/AU1006701A/en
Publication of WO2001030324A2 publication Critical patent/WO2001030324A2/en
Publication of WO2001030324A3 publication Critical patent/WO2001030324A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to a use of acetylsalicylic acid and/or derivatives thereof for production of a medicament for treatment of a prostatic hyperplasia, in particular the benign form of said prostatic hyperplasia.
PCT/AT2000/000282 1999-10-27 2000-10-27 Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia WO2001030324A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU10067/01A AU1006701A (en) 1999-10-27 2000-10-27 Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT180699 1999-10-27
ATA1806/99 1999-10-27

Publications (2)

Publication Number Publication Date
WO2001030324A2 WO2001030324A2 (en) 2001-05-03
WO2001030324A3 true WO2001030324A3 (en) 2001-11-22

Family

ID=3521381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2000/000282 WO2001030324A2 (en) 1999-10-27 2000-10-27 Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia

Country Status (2)

Country Link
AU (1) AU1006701A (en)
WO (1) WO2001030324A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2454923B (en) * 2007-11-23 2011-04-20 Ivy Medical Chemicals Plc Pharmaceutical compositions
HUP1400294A2 (en) * 2014-06-13 2015-12-28 Skillpharm Kft Novel application of clopidogrel

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437838A1 (en) * 1978-07-25 1980-04-30 Roecar Holdings Nv Prostaglandin inhibitors for benign adenoma of the prostate - includes salicylic, anthranilic and phenylacetic acid derivs., indole(s), indene(s), pyrrole(s) and pyrazolidine(s)
AU2667788A (en) * 1987-12-08 1989-06-08 Spyros Carantinos A medicament
EP0372676A1 (en) * 1988-12-08 1990-06-13 Spyros Carantinos Therapeutic preparation and method
JPH08268886A (en) * 1995-03-31 1996-10-15 Eisai Co Ltd Suppressing agent for vascularization
GB2306109A (en) * 1997-02-07 1997-04-30 John Wright A zinc containing composition for treating the common cold

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437838A1 (en) * 1978-07-25 1980-04-30 Roecar Holdings Nv Prostaglandin inhibitors for benign adenoma of the prostate - includes salicylic, anthranilic and phenylacetic acid derivs., indole(s), indene(s), pyrrole(s) and pyrazolidine(s)
AU2667788A (en) * 1987-12-08 1989-06-08 Spyros Carantinos A medicament
EP0372676A1 (en) * 1988-12-08 1990-06-13 Spyros Carantinos Therapeutic preparation and method
JPH08268886A (en) * 1995-03-31 1996-10-15 Eisai Co Ltd Suppressing agent for vascularization
GB2306109A (en) * 1997-02-07 1997-04-30 John Wright A zinc containing composition for treating the common cold

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198931, Derwent World Patents Index; Class B05, AN 1989-220777, XP002166364 *
DATABASE WPI Section Ch Week 199651, Derwent World Patents Index; Class B05, AN 1996-514903, XP002166363 *
DRAGO J R ET AL: "CONTROL OF METASTASES IN THE NB RAT PROSTATIC ADENO CARCINOMA MODEL", JOURNAL OF ANDROLOGY, vol. 5, no. 4, 1984, pages 265 - 268, XP000992681, ISSN: 0196-3635 *
LIM JIN T E ET AL: "Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.", BIOCHEMICAL PHARMACOLOGY, vol. 58, no. 7, 1 October 1999 (1999-10-01), pages 1097 - 1107, XP000992673, ISSN: 0006-2952 *
NELSON JON E ET AL: "Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study.", ONCOLOGY REPORTS, vol. 7, no. 1, January 2000 (2000-01-01), pages 169 - 170, XP000992647, ISSN: 1021-335X *
VILJOEN THEORICKUS C ET AL: "Influence of acetylsalicylic acid and metabolites on DU-145 prostatic cancer cell proliferation.", ONCOLOGY (BASEL), vol. 52, no. 6, 1995, pages 465 - 469, XP000992674, ISSN: 0030-2414 *

Also Published As

Publication number Publication date
WO2001030324A2 (en) 2001-05-03
AU1006701A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
WO2001095899A8 (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2003013541A8 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
IL130762A (en) Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia
WO2001066564A3 (en) Gamma-secretase inhibitors
HK1047575A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containingthe same.
WO2001000190A3 (en) Hyaluronic acid derivatives for the prevention and treatment of cutaneous scars
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
ZA200301269B (en) Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV.
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
WO2000069255A8 (en) Anti-inflammatory therapy for inflammatory mediated infection
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
AU2001232348A1 (en) Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
WO2001045650A3 (en) Cosmetic use of the residues from wine production
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
WO2002000208A3 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents
WO2001030324A3 (en) Use of acetylsalicylic acid and a preparation for treatment of prostatic hyperplasia
EP1190716A4 (en) The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof
WO2000069841A3 (en) Benzofuranylaminoalcohols
WO2000061125A3 (en) Osanetant in the treatment of mood disorders
WO2001022917A8 (en) Effervescent compositions comprising nimesulide
AU2001274000A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
WO2002017905A3 (en) Treatment of burns

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: AT

Ref document number: 2000 9179

Date of ref document: 20010503

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 20009179

Country of ref document: AT

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP